Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 7/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 3/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 2/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048938 | 0.81 | MELK (0.32) | QPCTTEKEPHB4 | |
| SCHEMBL3046204 | 0.81 | HTR5A (0.36) | TEKEPHB4 | |
| SCHEMBL3051515 | 0.80 | HTT (0.37) | HTTQPCTNAMPTAGTR1AGTR2 | |
| SCHEMBL3051307 | 0.80 | QPCTL (0.39) | NAMPTSYKTEK | |
| SCHEMBL3039722 | 0.79 | TEK (0.34) | QPCTTEKEPHB4 | |
| SCHEMBL3044505 | 0.79 | HTR5A (0.35) | TEKEPHB4 | |
| SCHEMBL3047524 | 0.77 | TEK (0.34) | QPCTTEKEPHB4 | |
| SCHEMBL3049056 | 0.77 | TEK (0.34) | QPCTTEKEPHB4 | |
| SCHEMBL3041841 | 0.76 | TEK (0.34) | QPCTTEKEPHB4 | |
| Trifluoroacetic Acid SCHEMBL3047191 | 0.75 | HDAC1 (0.45) | HTTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HTT 1472/4885QPCT 1796/4885CTSL 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.